MAPT and Alzheimer disease: In previous research studies, plasma pTau217 has consistently shown exceptionally high accuracy across different platforms and has demonstrated strong correlations with other markers of AD (CSF biomarkers, amyloid PET and Tau PET) and with neuropathology[30].